Rajiv Kaul is a sector portfolio manager for Fidelity Investments. Fidelity Investments is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing and other financial products and services to more than 20 million individuals, institutions, and financial intermediaries.

Rajiv manages Fidelity Select Biotechnology Portfolio. Rajiv has spent over 26 years at Fidelity. During this period, he has been widely recognized for his leadership within the biotech industry by media outlets such as the Wall Street Journal, New York Times, Bloomberg, CNBC, USA Today, and Barron’s to name a few. He is often ranked among the top-rated healthcare investors in the US. Over the last decade he has been a four-time Lipper Award winner for outstanding investment performance within the Biotechnology and Healthcare industry.

Rajiv is a member of the Research Advisory Council at Massachusetts General Hospital (MGH). MGH is the teaching hospital for Harvard Medical School and is often rated the top hospital in America by US News & World Report. He is also a member of the Board of Overseers at Scripps Research Institute, La Jolla, CA. He is the founder and sponsor of the Rajiv Kaul Stem Cell Research Fund at Boston Children’s Hospital.

He is a graduate of Harvard University and worked at McKinsey & Company prior to joining Fidelity.